Affinium Pharma, Inc.: Series A $18M

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

Trius Therapeutics, Inc.: Series A $20M

Tirus Therapeutics (San Diego, CA) a biopharmaceutical company developing next generation antibacterial drugs closed a $20M Series A round. The deal was led by Sofinnova Ventures and joined by InterWest Partners, Prism VentureWorks and Versant Ventures.

Trius Therapeutics, Inc.: Series A $20M

Trius Therapeutics (San Diego, CA) a developer of antibacterial drugs for the treatment of a broad range of infections, raised $20M Series A financing,, The round was led by Sofinnova Ventures, InterWest Partners, Prism VentureWorks and Versant Ventures.

Targanta, Inc.: Series C $70M

Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.